The Antibody Society

the official website of the antibody society

An international non-profit supporting antibody-related research and development.

Thanks to all who participated in Antibody Engineering & Therapeutics Europe!

by

Another very successful Antibody Engineering & Therapeutics Europe has concluded!

The Antibody Society thanks all the volunteers who helped at the booth:

 

  • Demelza Willemsz (Genmab)
  • Thomas Wesselink (Genmab)
  • Chalana Zilvold – van den Oever (Genmab)
  • Charlotte Berendsen (Genmab)
  • Lisa King (Amsterdam UMC)
  • Milon de Jong (Amsterdam UMC)

In addition to Thomas, Milon and Lisa, Kerry Chester (Board of Directors member), Janine Schuurman (Society Vice President) and Sally Ward (Society President) appear in the image above.

We hope to see you in Amsterdam in June 2023 for the next Antibody Engineering & Therapeutics Europe.

European Commission approves Lunsumio for people with relapsed or refractory follicular lymphoma

by

On June 8, 2022, Roche announced that the European Commission granted conditional marketing authorization for Lunsumio® (mosunetuzumab), a T-cell engaging bispecific antibody that targets CD20 and CD3, for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least two prior systemic therapies. Mosunetuzumab (RG7828, BTCT4465A) is an aglycosylated (N297G) humanized IgG1k bispecific antibody constructed using knobs-into-holes technology.

The approval is based on positive results from the Phase I/II GO29781 study (NCT02500407) in which Lunsumio demonstrated high complete response rates, with the majority of complete responders maintaining responses for at least 18 months, and favorable tolerability in people with heavily pre-treated FL. After a median follow-up of 18.3 months, the median duration of response among responders was 22.8 months (95% CI: 9.7-not estimable), the complete response rate was 60% (n=54/90), the objective response rate was 80% (n=72/90). Lunsumio is currently being evaluated in two Phase 3 studies: CELESTIMO, investigating Lunsumio plus lenalidomide in second line plus (2L+) FL, and SUNMO, investigating Lunsumio plus Polivy® (polatuzumab vedotin) in 2L+ diffuse large B-cell lymphoma.

Join us on June 9th for our next webinar – Registration is open!

by

In this webinar, Drs. Deane, Raybould and Boyles will share examples of how structure prediction enriches antibody sequence data and provide practical guidance for getting started using Oxford Protein Informatics Group (OPIG) tools to structurally featurise your antibody sequences. In particular, they will demonstrate the added value to tasks such as antibody functional clustering, repertoire disease-response diagnosis, and virtual screening.

Speaker bios are here.

Registration is open!

2022 Science Writing Competition winners announced!

by

Congratulations to our winners!

To make science accessible, clear, concise communication is essential. The Antibody Society thus offers our student and post-doctoral fellow members a chance to grow this skill through a Science Writing Competition. Entrants submitted essays of 1200 – 1500 words on a topic related to antibody research that were evaluated by our panel of judges.

Our post-doc and student winners are:

Dr. Finn Wolfreys, University of California, San Francisco, CA, USA

Essay title: Antibody Discovery’s Diversity Problem

Alexander Brown, University of Colorado Anschutz Medical Campus, Aurora, CO, USA

Essay title: Immunity in a Deck of Cards

The winning essays can be accessed via the links above.

View all winning essays from the
Science Writing Competitions here

The  next Science Writing Competition opens in Feb. 2023.

Thanks to everyone who participated!

Our Antibody Research Competition is open!

by

Attention Students & Post-docs!

 

 

Each year, The Antibody Society sponsors competitions to recognize and encourage the research activities of promising student/postdoctoral fellows.

We invite you to submit a summary of your work on a topic related to antibody research. While such summaries are traditionally presented as posters, feel free to be creative and present the content in other formats, such as video.

Relevant topics include, but are not limited to:

  • Antibody engineering or design
  • Antibody therapeutics
  • Fc effector functions
  • Bispecific antibodies
  • Antibody-drug conjugates
  • Adaptive immune receptor repertoires

The winning antibody research will be featured on The Antibody Society’s website and winners will receive a $400 USD cash prize.

Two winners (1 student, 1 post-doc) will be selected by our panel of judges based on the originality, creativity, scientific merit, and clarity of their research and its presentation.

Send your entry to membership@antibodysociety.org. The first 30 submissions will be considered for the competition. Please include your contact details and whether you are a student or post-doc in your email.

Submission deadline: July 15, 2022

Entry is limited to The Antibody Society student and post-doc members.
Not a member? Register here for your free membership!

Please note that all entrants must abide by the competition rules found here.